Table 15, Summary of included studies for primary care versus secondary care subgroup analysis for comparison 1d TCAs versus placebo - Service delivery Models and settings for delivery of services

Table 15Summary of included studies for primary care versus secondary care subgroup analysis for comparison 1d TCAs versus placebo

Study	Population	Intervention	Comparison	Comments
Primary care (K=6, N=597)
Barge-Schaapveld 2002 RCT Netherlands	Primary care N=63 Baseline severity: More severe Mean age (years): 43.4 Sex (% female): 73 Ethnicity (% BME): NR	Imipramine 200mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms endpoint
Blashki 1971 RCT Australia	Primary care N=45 Baseline severity: More severe Mean age (years): 36.7 Sex (% female): 100 Ethnicity (% BME): NR	Amitriptyline 75mg/day or 150mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms endpoint Depression symptoms change score
Lecrubier 1997a RCT France, Italy & UK	Primary care N=151 Baseline severity: More severe Mean age (years): 40.6 Sex (% female): 66 Ethnicity (% BME): NR	Imipramine 75-150mg/day	Placebo	Treatment duration (weeks): 13 Outcomes (for primary versus secondary care subgroup analysis): Response
Mynors-Wallis 1995a RCT UK	Primary care N=61 Baseline severity: More severe Mean age (years): 37.1 Sex (% female): 74 Ethnicity (% BME): 5	Amitriptyline maximum 150mg/day	Placebo	Treatment duration (weeks): 12 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms endpoint Depression symptoms change score
Philipp 1999 RCT Germany	Primary care N=157 Baseline severity: More severe Mean age (years): 46.5 Sex (% female): 75 Ethnicity (% BME): NR	Imipramine 100mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score Response
Schweizer 1998 RCT US	Primary care N=120 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Imipramine 50-150mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis): Response
Secondary care (K=30, N=3,444)
29060 07 001a RCT US	Secondary care N=25 Baseline severity: More severe Mean age (years): 44.8 Sex (% female): 52 Ethnicity (% BME): NR	Amitriptyline (dose NR)	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score
Amsterdam 1986 RCT US	Secondary care N=109 Baseline severity: More severe Mean age (years): 41 Sex (% female): 33 Ethnicity (% BME): NR	Amitriptyline 200-600mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms endpoint Depression symptoms change score Response
Bakish 1992b RCT Canada	Secondary care N=115 Baseline severity: More severe Mean age (years): 43 Sex (% female): 43 Ethnicity (% BME): NR	Amitriptyline 150mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
Bremner 1995a RCT US	Secondary care N=100 Baseline severity: More severe Mean age (years): 38.0 Sex (% female): 72 Ethnicity (% BME): NR	Amitriptyline 40-280mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
Byerley 1988a RCT US	Secondary care N=63 Baseline severity: More severe Mean age (years): 38.5 Sex (% female): 61 Ethnicity (% BME): NR	Imipramine 150-300mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms endpoint Response
Cassano 1986 RCT US, Canada, UK, & France	Secondary care N=314 Baseline severity: More severe Mean age (years): 41.7 Sex (% female): 62 Ethnicity (% BME): NR	Imipramine 50-300mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for primary versus secondary care subgroup analysis): Response
Elkin 1989/Imber 1990b RCT US	Secondary care N=125 Baseline severity: More severe Mean age (years): 35 Sex (% female): 70 Ethnicity (% BME): 11	Imipramine (mean final dose 185mg/day)	Placebo	Treatment duration (weeks): 16 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms endpoint Depression symptoms change score
Escobar 1980a RCT Colombia	Secondary care N=27 Baseline severity: More severe Mean age (years): 46.1 Sex (% female): 59 Ethnicity (% BME): NR	Imipramine 100-300mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for primary versus secondary care subgroup analysis): Response
Fabre 1992a RCT US	Secondary care N=80 Baseline severity: More severe Mean age (years): 35.5 Sex (% female): 66 Ethnicity (% BME): NR	Imipramine 65-275mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score
Feiger 1996 RCT US	Secondary care N=81 Baseline severity: More severe Mean age (years): 39.7 Sex (% female): 56 Ethnicity (% BME): 11	Imipramine 50-300mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis): Response
Feighner 1982 RCT US	Secondary care N=139 Baseline severity: More severe Mean age (years): NR Sex (% female): 71 Ethnicity (% BME): NR	Lofepramine 105-280mg/day or Imipramine 75-200mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms endpoint Response
Feighner 1989b RCT US	Secondary care N=30 Baseline severity: More severe Mean age (years): 44 Sex (% female): 50 Ethnicity (% BME): NR	Imipramine 50-250mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
Fontaine 1994 RCT Canada	Secondary care N=90 Baseline severity: More severe Mean age (years): 43.1 Sex (% female): 58 Ethnicity (% BME): NR	Imipramine 50-250mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
Goldberg 1980a RCT US	Secondary care N=122 Baseline severity: More severe Mean age (years): 36.1 Sex (% female): 74 Ethnicity (% BME): NR	Amitriptyline 75-200mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
Kusalic 1993 RCT Canada	Secondary care N=28 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Amitriptyline (mean final dose 109.93mg/day)	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
McCallum 1975 RCT US	Secondary care N=24 Baseline severity: More severe Mean age (years): 41.5 Sex (% female): 83 Ethnicity (% BME): NR	Amitriptyline 150mg/day	Placebo	Treatment duration (weeks): 3 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms endpoint Depression symptoms change score
MIR 003-020 (FDA)^a RCT US	Secondary care N=86 Baseline severity: More severe Mean age (years): 44.0 Sex (% female): 55 Ethnicity (% BME): NR	Amitriptyline 40-280mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score Response
Peselow 1989aa RCT US	Secondary care N=71 Baseline severity: More severe Mean age (years): 44.7 Sex (% female): 35 Ethnicity (% BME): NR	Imipramine 65-275mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
Peselow 1989ba RCT US	Secondary care N=82 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Imipramine 65-275mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
Reimherr 1990a RCT US & Canada	Secondary care N=299 Baseline severity: More severe Mean age (years): 39.0 Sex (% female): 54 Ethnicity (% BME): 9	Amitriptyline 50-150mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score Response
Rickels 1982e RCT US	Secondary care N=97 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Imipramine 150-200mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for primary versus secondary care subgroup analysis): Response
Rickels 1991 RCT US	Secondary care N=131 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Imipramine minimum 150mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
Rickels 1995_Study 006-1 RCT US	Secondary care N=77 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Imipramine 100-300mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis): Response
Rickels 1995_Study 006-2 RCT US	Secondary care N=80 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Imipramine 100-300mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis): Response
Schweizer 1994a RCT US	Secondary care N=151 Baseline severity: More severe Mean age (years): 42.5 Sex (% female): 64 Ethnicity (% BME): NR	Imipramine 75-225mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score Response
SER 315 (FDA)^a RCT Europe	Secondary care N=157 Baseline severity: More severe Mean age (years): 43.5 Sex (% female): 75 Ethnicity (% BME): NR	Amitriptyline 50-200mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score
Silverstone 1994 RCT UK	Secondary care N=166 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Imipramine 150mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms endpoint Depression symptoms change score Response
Smith 1990a RCT US	Secondary care N=100 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Amitriptyline 80-280mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Response
Stark 1985a RCT US	Secondary care N=355 Baseline severity: More severe Mean age (years): 41.5 Sex (% female): 68 Ethnicity (% BME): NR	Imipramine 100-300mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score Response
White 1984 RCT US	Secondary care N=120 Baseline severity: More severe Mean age (years): 37.1 Sex (% female): 48 Ethnicity (% BME): NR	Nortriptyline 75-150mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score

Study

Population

Intervention

Comparison

Comments

Primary care (K=6, N=597)

Barge-Schaapveld 2002

RCT

Netherlands

Primary care

N=63

Baseline severity: More severe

Mean age (years): 43.4

Sex (% female): 73

Ethnicity (% BME): NR

Imipramine 200mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms endpoint

Blashki 1971

RCT

Australia

Primary care

N=45

Baseline severity: More severe

Mean age (years): 36.7

Sex (% female): 100

Ethnicity (% BME): NR

Amitriptyline 75mg/day or 150mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score

Lecrubier 1997a

RCT

France, Italy & UK

Primary care

N=151

Baseline severity: More severe

Mean age (years): 40.6

Sex (% female): 66

Ethnicity (% BME): NR

Imipramine 75-150mg/day

Placebo

Treatment duration (weeks): 13

Outcomes (for primary versus secondary care subgroup analysis):

Response

Mynors-Wallis 1995a

RCT

Primary care

N=61

Baseline severity: More severe

Mean age (years): 37.1

Sex (% female): 74

Ethnicity (% BME): 5

Amitriptyline maximum 150mg/day

Placebo

Treatment duration (weeks): 12

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score

Philipp 1999

RCT

Germany

Primary care

N=157

Baseline severity: More severe

Mean age (years): 46.5

Sex (% female): 75

Ethnicity (% BME): NR

Imipramine 100mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms change score
Response

Schweizer 1998

RCT

Primary care

N=120

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Imipramine 50-150mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for primary versus secondary care subgroup analysis):

Response

Secondary care (K=30, N=3,444)

29060 07 001a

RCT

Secondary care

N=25

Baseline severity: More severe

Mean age (years): 44.8

Sex (% female): 52

Ethnicity (% BME): NR

Amitriptyline (dose NR)

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms change score

Amsterdam 1986

RCT

Secondary care

N=109

Baseline severity: More severe

Mean age (years): 41

Sex (% female): 33

Ethnicity (% BME): NR

Amitriptyline 200-600mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Response

Bakish 1992b

RCT

Canada

Secondary care

N=115

Baseline severity: More severe

Mean age (years): 43

Sex (% female): 43

Ethnicity (% BME): NR

Amitriptyline 150mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

Bremner 1995a

RCT

Secondary care

N=100

Baseline severity: More severe

Mean age (years): 38.0

Sex (% female): 72

Ethnicity (% BME): NR

Amitriptyline 40-280mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

Byerley 1988a

RCT

Secondary care

N=63

Baseline severity: More severe

Mean age (years): 38.5

Sex (% female): 61

Ethnicity (% BME): NR

Imipramine 150-300mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms endpoint
Response

Cassano 1986

RCT

US, Canada, UK, & France

Secondary care

N=314

Baseline severity: More severe

Mean age (years): 41.7

Sex (% female): 62

Ethnicity (% BME): NR

Imipramine 50-300mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for primary versus secondary care subgroup analysis):

Response

Elkin 1989/Imber 1990b

RCT

Secondary care

N=125

Baseline severity: More severe

Mean age (years): 35

Sex (% female): 70

Ethnicity (% BME): 11

Imipramine (mean final dose 185mg/day)

Placebo

Treatment duration (weeks): 16

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score

Escobar 1980a

RCT

Colombia

Secondary care

N=27

Baseline severity: More severe

Mean age (years): 46.1

Sex (% female): 59

Ethnicity (% BME): NR

Imipramine 100-300mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for primary versus secondary care subgroup analysis):

Response

Fabre 1992a

RCT

Secondary care

N=80

Baseline severity: More severe

Mean age (years): 35.5

Sex (% female): 66

Ethnicity (% BME): NR

Imipramine 65-275mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms change score

Feiger 1996

RCT

Secondary care

N=81

Baseline severity: More severe

Mean age (years): 39.7

Sex (% female): 56

Ethnicity (% BME): 11

Imipramine 50-300mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for primary versus secondary care subgroup analysis):

Response

Feighner 1982

RCT

Secondary care

N=139

Baseline severity: More severe

Mean age (years): NR

Sex (% female): 71

Ethnicity (% BME): NR

Lofepramine 105-280mg/day or Imipramine 75-200mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms endpoint
Response

Feighner 1989b

RCT

Secondary care

N=30

Baseline severity: More severe

Mean age (years): 44

Sex (% female): 50

Ethnicity (% BME): NR

Imipramine 50-250mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

Fontaine 1994

RCT

Canada

Secondary care

N=90

Baseline severity: More severe

Mean age (years): 43.1

Sex (% female): 58

Ethnicity (% BME): NR

Imipramine 50-250mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

Goldberg 1980a

RCT

Secondary care

N=122

Baseline severity: More severe

Mean age (years): 36.1

Sex (% female): 74

Ethnicity (% BME): NR

Amitriptyline 75-200mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

Kusalic 1993

RCT

Canada

Secondary care

N=28

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Amitriptyline (mean final dose 109.93mg/day)

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

McCallum 1975

RCT

Secondary care

N=24

Baseline severity: More severe

Mean age (years): 41.5

Sex (% female): 83

Ethnicity (% BME): NR

Amitriptyline 150mg/day

Placebo

Treatment duration (weeks): 3

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score

MIR 003-020 (FDA)^a

RCT

Secondary care

N=86

Baseline severity: More severe

Mean age (years): 44.0

Sex (% female): 55

Ethnicity (% BME): NR

Amitriptyline 40-280mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms change score
Response

Peselow 1989aa

RCT

Secondary care

N=71

Baseline severity: More severe

Mean age (years): 44.7

Sex (% female): 35

Ethnicity (% BME): NR

Imipramine 65-275mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

Peselow 1989ba

RCT

Secondary care

N=82

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Imipramine 65-275mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

Reimherr 1990a

RCT

US & Canada

Secondary care

N=299

Baseline severity: More severe

Mean age (years): 39.0

Sex (% female): 54

Ethnicity (% BME): 9

Amitriptyline 50-150mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms change score
Response

Rickels 1982e

RCT

Secondary care

N=97

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Imipramine 150-200mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for primary versus secondary care subgroup analysis):

Response

Rickels 1991

RCT

Secondary care

N=131

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Imipramine minimum 150mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

Rickels 1995_Study 006-1

RCT

Secondary care

N=77

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Imipramine 100-300mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for primary versus secondary care subgroup analysis):

Response

Rickels 1995_Study 006-2

RCT

Secondary care

N=80

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Imipramine 100-300mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for primary versus secondary care subgroup analysis):

Response

Schweizer 1994a

RCT

Secondary care

N=151

Baseline severity: More severe

Mean age (years): 42.5

Sex (% female): 64

Ethnicity (% BME): NR

Imipramine 75-225mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms change score
Response

SER 315 (FDA)^a

RCT

Europe

Secondary care

N=157

Baseline severity: More severe

Mean age (years): 43.5

Sex (% female): 75

Ethnicity (% BME): NR

Amitriptyline 50-200mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms change score

Silverstone 1994

RCT

Secondary care

N=166

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Imipramine 150mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Response

Smith 1990a

RCT

Secondary care

N=100

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Amitriptyline 80-280mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Response

Stark 1985a

RCT

Secondary care

N=355

Baseline severity: More severe

Mean age (years): 41.5

Sex (% female): 68

Ethnicity (% BME): NR

Imipramine 100-300mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms change score
Response

White 1984

RCT

Secondary care

N=120

Baseline severity: More severe

Mean age (years): 37.1

Sex (% female): 48

Ethnicity (% BME): NR

Nortriptyline 75-150mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for primary versus secondary care subgroup analysis):

Depression symptoms change score

a: Three-armed trial but where possible the demographics reported here are for only the two relevant arms.
: BME: black, minority, ethnic; K: number of studies; mg: milligrams; N: number of participants; NR: not reported; RCT: randomised controlled trial.

From: Service delivery Models and settings for delivery of services

Cover of Service delivery Models and settings for delivery of services

Service delivery Models and settings for delivery of services: Depression in adults: Evidence review A.

NICE Guideline, No. 222.

London: National Institute for Health and Care Excellence (NICE); 2022 Jun.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.